These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 21169390)

  • 21. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs.
    Newcomer JW
    J Clin Psychiatry; 2004; 65 Suppl 18():36-46. PubMed ID: 15600383
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of lifestyle intervention and metformin on weight management and markers of metabolic syndrome in obese adolescents.
    Harden KA; Cowan PA; Velasquez-Mieyer P; Patton SB
    J Am Acad Nurse Pract; 2007 Jul; 19(7):368-77. PubMed ID: 17680902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents.
    Arman S; Sadramely MR; Nadi M; Koleini N
    Saudi Med J; 2008 Aug; 29(8):1130-4. PubMed ID: 18690305
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia.
    Weiden PJ
    J Clin Psychiatry; 2007; 68 Suppl 4():34-9. PubMed ID: 17539698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia.
    Casey DE; Haupt DW; Newcomer JW; Henderson DC; Sernyak MJ; Davidson M; Lindenmayer JP; Manoukian SV; Banerji MA; Lebovitz HE; Hennekens CH
    J Clin Psychiatry; 2004; 65 Suppl 7():4-18; quiz 19-20. PubMed ID: 15151456
    [No Abstract]   [Full Text] [Related]  

  • 26. Interventions to reduce weight gain in schizophrenia.
    Faulkner G; Cohn T; Remington G
    Schizophr Bull; 2007 May; 33(3):654-6. PubMed ID: 17449900
    [No Abstract]   [Full Text] [Related]  

  • 27. The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents: a meta-analysis.
    Ehret M; Goethe J; Lanosa M; Coleman CI
    J Clin Psychiatry; 2010 Oct; 71(10):1286-92. PubMed ID: 20441727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antipsychotic medications: metabolic and cardiovascular risk.
    Newcomer JW
    J Clin Psychiatry; 2007; 68 Suppl 4():8-13. PubMed ID: 17539694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Schizophrenia and comorbid metabolic disorders.
    Henderson DC
    J Clin Psychiatry; 2005; 66 Suppl 6():11-20. PubMed ID: 16107179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Considering metformin in cardiometabolic protection in psychosis.
    Curtis J; Newall H; Myles N; Shiers D; Samaras K
    Acta Psychiatr Scand; 2012 Oct; 126(4):302-3. PubMed ID: 22804349
    [No Abstract]   [Full Text] [Related]  

  • 31. Management of weight gain in patients with schizophrenia.
    Aquila R
    J Clin Psychiatry; 2002; 63 Suppl 4():33-6. PubMed ID: 11913674
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms.
    Reynolds GP; Kirk SL
    Pharmacol Ther; 2010 Jan; 125(1):169-79. PubMed ID: 19931306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The metabolic syndrome and schizophrenia.
    Meyer JM; Stahl SM
    Acta Psychiatr Scand; 2009 Jan; 119(1):4-14. PubMed ID: 19133915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Therapeutic options for weight management in schizophrenic patients treated with atypical antipsychotics].
    Cordes J; Sinha-Röder A; Kahl KG; Malevani J; Thuenker J; Lange-Asschenfeldt C; Hauner H; Agelink MW; Klimke A
    Fortschr Neurol Psychiatr; 2008 Dec; 76(12):703-14. PubMed ID: 18924059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of metformin for weight management in patients without type 2 diabetes.
    Desilets AR; Dhakal-Karki S; Dunican KC
    Ann Pharmacother; 2008 Jun; 42(6):817-26. PubMed ID: 18477733
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine.
    Siskind D; Friend N; Russell A; McGrath JJ; Lim C; Patterson S; Flaws D; Stedman T; Moudgil V; Sardinha S; Suetani S; Kisely S; Winckel K; Baker A
    BMJ Open; 2018 Mar; 8(3):e021000. PubMed ID: 29500217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Second-generation antipsychotic use in schizophrenia and associated weight gain: a critical review and meta-analysis of behavioral and pharmacologic treatments.
    Das C; Mendez G; Jagasia S; Labbate LA
    Ann Clin Psychiatry; 2012 Aug; 24(3):225-39. PubMed ID: 22860242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic complications of schizophrenia and antipsychotic medications--an updated review.
    Yogaratnam J; Biswas N; Vadivel R; Jacob R
    East Asian Arch Psychiatry; 2013 Mar; 23(1):21-8. PubMed ID: 23535629
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics.
    Cernea S; Dima L; Correll CU; Manu P
    Drugs; 2020 Nov; 80(17):1763-1781. PubMed ID: 32930957
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials.
    Wu RR; Zhang FY; Gao KM; Ou JJ; Shao P; Jin H; Guo WB; Chan PK; Zhao JP
    Mol Psychiatry; 2016 Nov; 21(11):1537-1544. PubMed ID: 26809842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.